Literature DB >> 15760805

The pharmacokinetics of oxycodone.

Ralph A Lugo1, Steven E Kern.   

Abstract

Oxycodone is among the most commonly used opioid analgesics for the relief of moderate-to-severe pain and is pharmacodynamically comparable to morphine. Oxycodone is available in the United States in oral dosage forms and controlled-release tablets. Studies have demonstrated marked interindividual variation in the pharmacokinetics of oxycodone. The pharmacokinetics of oral oxycodone differs from oral morphine in that it has a higher bioavailability, a slightly longer half-life, and is hepatically metabolized by cytochrome P450 rather than undergoing glucuronidation. Understanding oxycodone pharmacokinetics favors safe and effective use of this analgesic in a wide variety of patients with different levels of organ function. A MEDLINE search was conducted to identify literature published between 1966 and May 2004 relevant to the pharmacokinetics of oxycodone. These publications were reviewed and the literature summarized regarding unique and clinically important elements of oxycodone disposition including its absorption profile (immediate release, controlled release, rectal administration, and intranasal administration), distribution, and its metabolism/excretion. Special populations, including children and those with liver/renal failure, have a unique oxycodone pharmacokinetic profile that must be taken into account in order to maximize analgesic efficacy and reduce the risk of adverse events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15760805     DOI: 10.1300/j354v18n04_03

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  25 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?

Authors:  Janet Hardy; Ross Norris; Helen Anderson; Angela O'Shea; Bruce Charles
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

3.  Opioid-induced neurotoxicity.

Authors:  Romayne Gallagher
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

4.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

Review 5.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

6.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

7.  Escalated Oxycodone Self-Administration Causes Differential Striatal mRNA Expression of FGFs and IEGs Following Abstinence-Associated Incubation of Oxycodone Craving.

Authors:  Christopher A Blackwood; Michael Leary; Aaron Salisbury; Michael T McCoy; Jean Lud Cadet
Journal:  Neuroscience       Date:  2019-07-24       Impact factor: 3.590

Review 8.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

9.  Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects.

Authors:  Rolf Terlinden; Joachim Ossig; Frank Fliegert; Claudia Lange; Karin Göhler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jul-Sep       Impact factor: 2.441

10.  Analgesics in patients with hepatic impairment: pharmacology and clinical implications.

Authors:  Marija Bosilkovska; Bernhard Walder; Marie Besson; Youssef Daali; Jules Desmeules
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.